Researchers from Tempus partnered with Mayo Clinic to study individuals with breast cancer subjected to Tempus xT tumor-normal matched sequencing.

Most studies of hereditary breast cancer have focused only a small-subset of patients with an aggressive disease known as Triple Negative Breast Cancer. This study seeks to improve our understanding of all breast cancer patients by exploring the molecular features of their tumors to identify hereditary mutations, and other features that will uncover potential areas for therapeutic targeting. 

“This study identified several unique aspects in the genetic profile of breast cancer tumors in carriers of germline pathogenic variants in ATM, BRCA1, BRCA2,CHEK2 and PALB2,” said Siddhartha Yadav, MBBS, MD, Associate Professor of Oncology at the Mayo Clinic. “Ultimately, these findings have significant implications for better understanding how breast cancer develops in individuals with these germline mutations, and will help identify more effective treatment strategies for managing hereditary breast cancer.”

This study was presented at the San Antonio Breast Cancer Symposium in 2023.